Development and Validation of RP-HPLC-UV Method for Determination of Diclofenac Sodium Residues on Surfaces for Cleaning Validation Detection of Diclofenac Sodium Residues on Pharmaceutical Manufacturing Equipment Surfaces by HPLC Method
Iranian Journal of Pharmaceutical Sciences,
Vol. 15 No. 4 (2019),
1 October 2019
,
Page 11-30
https://doi.org/10.22037/ijps.v15.40451
Abstract
In recent years, cleaning validation has achieved a position of increasing in the pharmaceutical industry. It provides assurance to the cleaning procedure that ensures equipment is consistently cleaned from the product, detergent and microbial residues to an acceptable level to avoid cross contamination and adulteration of drug product with other active ingredients. The aim of this study was to demonstrate the applicability of reversedphase high-performance liquid chromatography coupled with UV detector (RP-HPLC-UV) method for determining the residues of Diclofenac sodium in cleaning control swab samples from equipment surfaces after manufacturing of Diclofenac sodium injection (75mg/3ml) in order to control a cleaning procedure. Diclofenac sodium was evaluated as the worst case. This API is sparingly soluble in water and adherent to surfaces. The acceptable residue limit (ARL) of Diclofenac sodium was calculated (0.75 μg/cm²). The analytical method was validated with respect to system suitability test, specificity, linearity-range, accuracy, Repeatability, intermediate precision, limit of detection (LOD) and quantitation (LOQ). These studies were performed in accordance with established guidelines, International Conference on Harmonisation ICH Q2 (R1). The precision of the swabbing procedure and stability of Diclofenac sodium standard solutions were also investigated. The swab sampling method was developed and optimized in order to obtain a suitable recovery (˃80%) from stainless steel surfaces 316L. Alpha Texwipe® TX761 polyester Swabs were moistened with diluent (mobile phase) a mixture of Acetonitrile-Water-Orthophosphoric Acid 85 % (600:400:1, v/v/v) (pH 2.5* ± 0.2). The HPLC method was developed in isocratic mode using Hypersil OctaDecylSilyle ODS C18 (250 × 4.6 mm, 5 μm) column at 25°C. At a flow rate of 1.2 ml/min, an injection volume of 20 μl. Detection was carried out at 235 nm. The retention time of Diclofenac sodium was 4.8 min. The calibration curve was linear (the coefficient of determination R²=0.9988) over a concentration range 0.05 μg/ml – 12.5 μg/ml. The intra-day, inter-day precision and precision of the swabbing procedure expressed as relative standard deviation were below 5%. The limit of detection and
quantitation were 0.014 μg/ml and 0.05 μg/ml respectively. The average recovery of the swabbing method obtained was 87.80 %, when two swabs moistened were used. It is evident that this proposed validated RPHPLC-UV method with the appropriate swabs Texwipe® TX761 procedure could be applicable for cleaning validation to detect traces levels of Diclofenac sodium residues on pharmaceutical manufacturing equipments.
- Cleaning Validation
- Diclofenac Sodium
- HPLC
- Quality Assurance
- Residue
- Swab Sampling
How to Cite
References
[2] Health Products and Food Branch Inspectorate. Guidance Document Cleaning Validation Guidelines, Guide-0028, Canada, (2008) 1-9.
[3] PDA Parenteral Drug Association. Guidance for Industry, Technical Report No. 29, Points to consider for cleaning validation, Washington, 52 (1998) 1-29.
[4] APIC Active Pharmaceutical ingredients Committee. Guidance on aspects of cleaning validation in active pharmaceutical ingredient plants, (2016) 1-56.
[5] EudraLex European Commission. EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Qualification and Validation, Brussels, (2015) 15 (4): 11-12.
[6] Eureka santé Vidal: Diclofenac sodium SANDOZ injectable 75 mg/3 ml, France.https://eurekasante.vidal.fr/medicaments/vidalfamille/medicament-gp2968-DICLOFENACSANDOZ-injectable.html (Accessed May 27, 2018).
[7] European pharmacopeia 9.0th edition, vol. 1.European Directorate for the Quality of Medicines & HealthCare (EDQM), France (2017) 2414.
[8] ICH Harmonised Triplicate Guideline. Validation of analytical Procedures, text and Methodology, International Conference on Harmonisation Q2 (R1), Geneva (2005) 1-13.
[9] Luciana Valéria P, Okasaki Fukumori N, Nakamura Matsuda M. Determination of the worst case for cleaning validation of equipment used in the radiopharmaceutical production of lyophilized reagents for 99mTc labeling. BJPS. (2016) 52 (1):105-112.
[10] Walsh A. Cleaning validation for the 21st century: acceptance limits for active pharmaceutical ingredients (APIs): Part I. Pharmaceutical Engineering (2011) 31 (4): 74-83.
[11] United States Pharmacopeia (USP) 30-NF 25.USP Monographs, Rockville MD (2007) 1922.
[12] Fourman G. L, Mullen M.V. Determining cleaning validation acceptance limits for pharmaceutical manufacturing operations. Pharm.Technol. (1993) 17 (4) : 54-60.
[13] EMA European Medicine Agency. Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities, United Kingdom (2014) 3-8.
[14] ANSM Agence nationale de sécurité du médicament et des produits de santé. Guide des bonnes pratiques de fabrication, Commission européenne, locaux et matériel, France (2016) (3) 22-25.
[15] ANSM Agence nationale de sécurité du médicament et des produits de santé. Guide des bonnes pratiques de fabrication, Commission européenne, production, France (2016) (5) 34-43.
[16] ICH Harmonised Triplicate Guideline. Impurities: guideline for residual solvents, International Conference on Harmonisation Q3C, Geneva (1997) 1-16.
[17] Bourgois S. La détermination du taux de recouvrement est une étape préliminaire, nécessaire lors d’un exercice de validation du nettoyage, A3P. La Vague N° 54 revue (2017): 41-42.
[18] Rubashvili I, Karukhnishvili N, Loria K, Dvali N.Validation of swab sampling and HPLC methods for determination of Meloxicam residues on pharmaceutical manufacturing equipment surfaces for cleaning validation. Turk. J. Pharm. Sci. (2015) 12 (3): 287-298.
[19] AZIERTA science to business; contract scientific support consulting: Diclofenac sodium ADE determination strategy LAB, Madrid (2018). https://azierta.eu/toxicologia/pde/#1459756928789-0d9f6100-77c9 (Accessed May 27, 2018).
[20] FDA Food and Drug Administration. Center for drug evaluation and research, public health service, pharmacology/toxicology NDA 22-396, Dyloject®Diclofenac sodium Intravenous injection, Washington
DC (2014) 99-102.
[21] ICH Harmonised Triplicate Guideline. Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients, Guidance for Industry, International Conference on Harmonisation Q7,Geneva (2016) 34-35.
[22] Klinkenberg R, Streel B, Ceccato A.Development and validation of a liquid chromatographic method for the determination of amlodipine residues on manufacturing equipment surfaces. J. Pharm. Biomed. Anal. (2003) 32 (2): 345-352.
[23] Vidal: Gentamicine Panpharma 80 mg/2ml solution injectable, France.https://www.vidal.fr/Medicament/gentamicine_panpha rma-7479.htm (Accessed May 27, 2018).
[24] EMA European Medicine Agency. VICH GL 18 residual solvents in new veterinary medicinal products, active substances and excipients, United Kingdom (2010) 5-7.
[25] WHO World Health Organization. Quality assurance of pharmaceuticals: a compendium of guidelines and related materials, 2nd edition, Good manufacturing practices and inspection, Geneva,(2007) 128.
[26] Cole-Parmer scientific experts: Effective Swabbing Techniques for Cleaning Validation, United States. https://www.coleparmer.com/techarticle/effective-swabbing-techniques (Accessed May 21, 2018).
[27] Goti P.P, Savsani J.J, Patel P.B. Development and validation of analytical method for estimation of Diclofenac sodium in swab samples. Int. J. Pharm.Sci. Res. (2013) 4 (2): 741-744.
[28] Sindhur Nag N, Gouthami B, Madhuri L, Krishnaveni N, Meyyanathan S, Suresh B.Development and validation of a RP-HPLC method for the simultaneous determination of paracetamol and Diclofenac potassium on stainless steel surface of pharmaceutical manufacturing equipments. JOCPR.(2012) 4 (3): 1670-1675.
- Abstract Viewed: 174 times
- IJPS_Volume 15_Issue 4_Pages 11-30 Downloaded: 74 times